Correlation between secreted protein acidic and rich in cysteine protein expression and the prognosis of postoperative patients exhibiting esophageal squamous cell carcinoma

Wu,Jian; Zhang,Jin‑Rong; Jiang,Xue‑Qiu; Cao,Xu‑Guang

doi:10.3892/mmr.2017.6959

Correlation between secreted protein acidic and rich in cysteine protein expression and the prognosis of postoperative patients exhibiting esophageal squamous cell carcinoma

Authors:
- Jian Wu
- Jin‑Rong Zhang
- Xue‑Qiu Jiang
- Xu‑Guang Cao
View Affiliations

Affiliations: Department of Laboratory Medicine, The First People's Hospital of Yancheng, Yancheng, Jiangsu 224005, P.R. China, Department of Laboratory Medicine, The People's Hospital of Dafeng, Yancheng, Jiangsu 224100, P.R. China
Published online on: July 12, 2017 https://doi.org/10.3892/mmr.2017.6959
Pages: 3401-3406

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between the expression level of secreted protein acidic and rich in cysteine (SPARC) and the prognosis of postoperative patients with esophageal squamous cell carcinoma (ESCC). The expression level of SPARC was detected in the 89 ESCC tissue cases and 100 healthy esophageal mucosa cases, which served as the controls. Immunohistochemistry and reverse transcription‑polymerase chain reaction (RT‑PCR) were employed to evaluate the SPARC expression in cases with ESCC. RT‑PCR demonstrated that the positive rates of SPARC mRNA expression in ESCC were 71.91% (64/89). The positive rates of normal esophageal mucosa mRNA expression were 15.00% (15/100), which were significantly lower than that in the ESCC tissue samples. The difference was statistically significant (P<0.001). Immunohistochemical staining indicated that the positive expression rate of SPARC protein in the ESCC tissue samples was significantly higher than that in the esophageal mucosa tissue samples (65.17 vs. 8.00%; P<0.001). The expression of SPARC protein was negatively correlated with lymph node metastasis (P<0.05), which was not associated with the pathologic gross morphology, tumor differentiation degree or other clinical features. The survival of patients with ESCC was not associated with the expression level of SPARC protein (P>0.05), but was associated with the tumor location (P<0.05), differentiation (P<0.001) and staging (P<0.05). Thus, SPARC mRNA and protein were highly expressed in ESCC, and negatively correlated with lymph node metastasis, which was not associated with postoperative survival of ESCC patients. Thus, detection of SPARC mRNA and protein expression levels may facilitate early diagnosis and prognosis assessment of ESCC.

View Figures

View References

1	Tustumi F, Takeda FR, Kimura CM, Sallum RA, Ribeiro U Junior and Cecconello I: Esophageal carcinoma: Is squamous cell carcinoma different disease compared to adenocarcinoma? A transversal study in a quaternary high volume hospital in Brazil. Arq Gastroenterol. 53:44–48. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhu YM, Zhang H, Ni S, Wang J, Li DZ and Liu SY: Multi-disciplinary treatment increases the survival rate of late stage pharyngeal, laryngeal or cervical esophageal cancers treated by free jejunal flap reconstruction after cancer resection. Zhonghua Zhong Liu Za Zhi. 38:389–394. 2016.(In Chinese). PubMed/NCBI
3	Huang XE, Wang L, Ji ZQ, Liu MY, Qian T and Li L: Safety of lienal polypeptide injection combined with chemotherapy in treating patients with advanced cancer. Asian Pac J Cancer Prev. 16:7837–7841. 2015. View Article : Google Scholar : PubMed/NCBI
4	Jia X, Liu P, Zhang M, Feng T, Tang H, Tang Z, Zhao H and Jin T: Genetic variants at 6p21, 10q23, 16q21 and 22q12 are associated with esophageal cancer risk in a Chinese Han population. Int J Clin Exp Med. 8:19381–19387. 2015.PubMed/NCBI
5	Zhang J, Jiang Y, Wu C, Cai S, Wang R, Zhen Y, Chen S, Zhao K, Huang Y, Luketich J and Chen H: Comparison of clinicopathologic features and survival between eastern and western population with esophageal squamous cell carcinoma. J Thorac Dis. 7:1780–1786. 2015.PubMed/NCBI
6	Nakamura R, Omori T, Takeuchi H, Kawakubo H, Takahashi T, Wada N, Saikawa Y and Kitagawa Y: Salvage endoscopic resection as a treatment for locoregional failure or recurrence following chemoradiotherapy or radiotherapy for esophageal cancer. Oncol Lett. 11:3631–3636. 2016.PubMed/NCBI
7	Gamboa AM, Kim S, Force SD, Staley CA, Woods KE, Kooby DA, Maithel SK, Luke JA, Shaffer KM, Dacha S, et al: Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. Cancer. 122:2150–2157. 2016. View Article : Google Scholar : PubMed/NCBI
8	Cho JW: The role of endosonography in the staging of gastrointestinal cancers. Clin Endosc. 48:297–301. 2015. View Article : Google Scholar : PubMed/NCBI
9	Anandarajah EM, Ditgen D, Hansmann J, Erttmann KD, Liebau E and Brattig NW: SPARC (secreted protein acidic and rich in cysteine) of the intestinal nematode Strongyloides ratti is involved in mucosa-associated parasite-host interaction. Mol Biochem Parasitol. 207:75–83. 2016. View Article : Google Scholar : PubMed/NCBI
10	Shi D, Jiang K, Fu Y, Fang R, Liu XI and Chen J: Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition. Oncol Lett. 11:3251–3258. 2016.PubMed/NCBI
11	Rossi MK, Gnanamony M and Gondi CS: The ‘SPARC’ of life: Analysis of the role of osteonectin/SPARC in pancreatic cancer (Review). Int J Oncol. 48:1765–7871. 2016.PubMed/NCBI
12	Rosset EM and Bradshaw AD: SPARC/osteonectin in mineralized tissue. Matrix Biol. 52–54:78–87. 2016. View Article : Google Scholar
13	Notaro A, Sabella S, Pellerito O, Vento R, Calvaruso G and Giuliano M: The secreted protein acidic and rich in cysteine is a critical mediator of cell death program induced by WIN/TRAIL combined treatment in osteosarcoma cells. Int J Oncol. 48:1039–1044. 2016.PubMed/NCBI
14	Tseng C and Kolonin MG: Proteolytic Isoforms of SPARC induce adipose stromal cell mobilization in obesity. Stem Cells. 34:174–190. 2016. View Article : Google Scholar : PubMed/NCBI
15	Kim H, Samuel S, Lopez-Casas P, Grizzle W, Hidalgo M, Kovar J, Oelschlager D, Zinn K, Warram J and Buchsbaum D: SPARC-independent delivery of Nab-Paclitaxel without depleting tumor stroma in patient-derived pancreatic cancer xenografts. Mol Cancer Ther. 15:680–688. 2016. View Article : Google Scholar : PubMed/NCBI
16	Vaz J, Ansari D, Sasor A and Andersson R: SPARC: A potential prognostic and therapeutic target in pancreatic cancer. Pancreas. 44:1024–1035. 2015. View Article : Google Scholar : PubMed/NCBI
17	Mattina J, MacKinnon N, Henderson VC, Fergusson D and Kimmelman J: Design and reporting of targeted anticancer preclinical studies: A meta-analysis of animal studies investigating sorafenib antitumor efficacy. Cancer Res. 76:4627–4636. 2016. View Article : Google Scholar : PubMed/NCBI
18	Huo Y, Su T, Cai Q and Macara IG: An in vivo gain-of-function screen identifies the Williams-Beuren Syndrome Gene GTF2IRD1 as a mammary tumor promoter. Cell Rep. 15:2089–2096. 2016. View Article : Google Scholar : PubMed/NCBI
19	Lee J, Katzenmaier EM, Kopitz J and Gebert J: Reconstitution of TGFBR2 in HCT116 colorectal cancer cells causes increased LFNG expression and enhanced N-acetyl-d-glucosamine incorporation into Notch1. Cell Signal. 28:1105–1113. 2016. View Article : Google Scholar : PubMed/NCBI
20	Gao R, Ma LQ, Du X, Zhang TT, Zhao L, Liu L, Liu JC, Guo F, Cheng Z and Huang H: Rnf25/AO7 positively regulates wnt signaling via disrupting Nkd1-Axin inhibitory complex independent of its ubiquitin ligase activity. Oncotarget. 7:23850–23859. 2016. View Article : Google Scholar : PubMed/NCBI
21	Fang M, Yuan J, Peng C and Li Y: Collagen as a double-edged sword in tumor progression. Tumour Biol. 35:2871–2882. 2014. View Article : Google Scholar : PubMed/NCBI
22	Bai J, Zhang X, Hu K, Liu B, Wang H, Li A, Lin F, Zhang L, Sun X, Du Z and Song J: Silencing DNA methyltransferase 1 (DNMT1) inhibits proliferation, metastasis and invasion in ESCC by suppressing methylation of RASSF1A and DAPK. Oncotarget. 7:44129–44141. 2016. View Article : Google Scholar : PubMed/NCBI
23	Liu JY, Lu JB and Xu Y: MicroRNA-153 inhibits the proliferation and invasion of human laryngeal squamous cell carcinoma by targeting KLF5. Exp Ther Med. 11:2503–2508. 2016.PubMed/NCBI
24	Lin W, Zhong M, Yin H, Chen Y, Cao Q, Wang C and Ling C: Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo. Oncol Rep. 36:961–967. 2016.PubMed/NCBI
25	Che Y, Luo A, Wang H, Qi J, Guo J and Liu Z: The differential expression of SPARC in esophageal squamous cell carcinoma. Int J Mol Med. 17:1027–1033. 2006.PubMed/NCBI
26	Xue LY, Zou SM, Zheng S, Liu XY, Wen P, Yuan YL, Lin DM and Lu N: Expressions of the γ2 chain of laminin-5 and secreted protein acidic and rich in cysteine in esophageal squamous cell carcinoma and their relation to prognosis. Chin J Cancer. 30:69–78. 2011. View Article : Google Scholar : PubMed/NCBI
27	Nagaraju GP and Sharma D: Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev. 37:559–566. 2011. View Article : Google Scholar : PubMed/NCBI
28	Zinovyeva MV, Monastyrskaya GS, Kopantzev EP, Vinogradova TV, Kostina MB, Sass AV, Filyukova OB, Uspenskaya NY, Sukhikh GT and Sverdlov ED: Identification of some human genes oppositely regulated during esophageal squamous cell carcinoma formation and human embryonic esophagus development. Dis Esophagus. 23:260–270. 2010. View Article : Google Scholar : PubMed/NCBI
29	Jakharia A, Borkakoty B and Singh S: Expression of SPARC like protein 1 (SPARCL1), extracellular matrix-associated protein is down regulated in gastric adenocarcinoma. J Gastrointest Oncol. 7:278–283. 2016.PubMed/NCBI
30	Porte H, Triboulet JP, Kotelevets L, Carrat F, Prévot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C and Chastre E: Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: Implications for prognosis. Clin Cancer Res. 4:1375–1382. 1998.PubMed/NCBI
31	Hong Y, Zhang J, Zhang H, Li X, Qu J, Zhai J, Zhang L, Chen F and Li T: Heterozygous PTCH1 mutations impact the bone metabolism in patients with nevoid basal cell carcinoma syndrome likely by regulating SPARC expression. J Bone Miner Res. 31:1413–1428. 2016. View Article : Google Scholar : PubMed/NCBI
32	Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, et al: A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. Br J Cancer. 114:524–531. 2016. View Article : Google Scholar : PubMed/NCBI
33	Slusser-Nore A, Larson-Casey JL, Zhang R, Zhou XD, Somji S, Garrett SH, Sens DA and Dunlevy JR: SPARC expression is selectively suppressed in tumor initiating urospheres isolated from As+3- and Cd+2-transformed human urothelial cells (UROtsa) stably transfected with SPARC. PLoS One. 11:e01473622016. View Article : Google Scholar : PubMed/NCBI